# A Prospective Interventional Study Assessing the Clinical and Operational Effectiveness of Transitioning From Mircera to Daprodustat for the Treatment of Anemia in End Stage Kidney Disease

Study · id `cardio:ct-nct05951192` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05951192](<https://clinicaltrials.gov/study/NCT05951192>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05951192

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 161 participants.

## Technical summary

Registry record NCT05951192. Allocation not applicable; no masking; primary purpose treatment. Start 2023-07-01 (actual); primary completion 2024-02-14 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 161 participants (enrolled count; ClinicalTrials.gov record NCT05951192, source copy `cardio:ctgov-nct05951192-2024-05-24`, retrieved 2026-10-26)
- Started: 2023-07-01 (actual) (ClinicalTrials.gov record NCT05951192, source copy `cardio:ctgov-nct05951192-2024-05-24`, retrieved 2026-10-26)
- Primary completion: 2024-02-14 (actual) (ClinicalTrials.gov record NCT05951192, source copy `cardio:ctgov-nct05951192-2024-05-24`, retrieved 2026-10-26)
- Completion: 2024-02-14 (actual) (ClinicalTrials.gov record NCT05951192, source copy `cardio:ctgov-nct05951192-2024-05-24`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT05951192, source copy `cardio:ctgov-nct05951192-2024-05-24`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05951192-2024-05-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Prospective Interventional Study Assessing the Clinical and Operational Effectiveness of Transitioning From Mircera to Daprodustat for the Treatment of Anemia in End Stage Kidney Disease
- Acronym: ROQ-IT
- Condition: Anemia
- Condition: Renal Insufficiency, Chronic
- Condition: Renal Anemia
- Intervention (Drug): Daprodustat
- Lead sponsor: USRC Kidney Research
- Lead sponsor class: NETWORK
- Collaborator: GlaxoSmithKline
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as a collaborator: GlaxoSmithKline (`cardio:org-glaxosmithkline`)

## Provenance

Content hash: ee660189e12aeeeee407bf648576517b224caa37169e5d8c90477d071ba87795
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
